- Record: found
- Abstract: not found
- Article: not found
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
Anas Younes ,
Jesus G Berdeja ,
Manish R Patel ,
Ian Flinn ,
John F Gerecitano ,
Sattva S Neelapu ,
Kevin R Kelly ,
Amanda R Copeland ,
Amy Akins ,
Myles S Clancy ,
Lucy Gong ,
Jing Wang ,
Anna Ma ,
Jaye L Viner ,
Yasuhiro Oki
May 2016
May 2016
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.